title: Yttrium 90 microspheres for the treatment of hepatocellular carcinoma.
abstract: Yttrium-90 microspheres are radioactive particles which are increasingly being employed for treating patients with unresectable hepatocellular carcinoma (HCC). The procedure is called radioembolization. It involves the injection of micron-sized embolic particles loaded with a radioisotope by use of transarterial techniques. Because of the sensitivity of liver parenchyma and relative insensitivity of tumor, external radiation has played a limited role in treating HCC. (90)Y administered via arterial route directs the highly concentrated radiation to the tumor while healthy liver parenchyma is relatively spared due to its preferential blood supply from portal venous blood. This technique has proven useful for the majority of patients with HCC as most of them present in advanced stage, beyond potentially curative options (resection/liver transplantation). (90)Y microspheres can be used in downstaging large tumors to bring within transplantable criteria, in patients with portal venous thrombosis due to tumor invasion and as palliative therapy. There are two available devices for (90)Y administration; TheraSphere® (glass based) and SIR-Spheres® (resin based). The procedure is performed on an outpatient basis. The incidence of complications is comparatively less and may include nausea, fatigue, abdominal pain, hepatic dysfunction, biliary injury, fibrosis, radiation pneumonitis, GI ulcers, and vascular injury; however, these can be avoided by meticulous pretreatment assessment, careful patient selection, and adequate dosimetry. This article explores the technical and clinical aspects of (90)Y radioembolization with keeping emphasis on patient selection, uses, and complications.
authors.affiliation: Department of Radiology, Northwestern Memorial Hospital, Robert H. Lurie Comprehensive Cancer Center, Chicago, IL, USA.
authors.forename: Khairuddin
authors.initials: K
authors.lastname: Memon
authors.forename: Robert J
authors.initials: RJ
authors.lastname: Lewandowski
authors.forename: Ahsun
authors.initials: A
authors.lastname: Riaz
authors.forename: Riad
authors.initials: R
authors.lastname: Salem
mesh_terms: D014408:Biomarkers, Tumor; D006528:Carcinoma, Hepatocellular / Q000532:radiotherapy* / Q000628:therapy; D004621:Embolization, Therapeutic / Q000009:adverse effects; D006801:Humans; D007261:Infusions, Intra-Arterial / Q000009:adverse effects; D008099:Liver / Q000098:blood supply; D008113:Liver Neoplasms / Q000532:radiotherapy* / Q000628:therapy; D008863:Microspheres; D018579:Patient Selection; D019275:Radiopharmaceuticals / Q000627:therapeutic use; D015021:Yttrium Radioisotopes / Q000009:adverse effects / Q000627:therapeutic use*
chemical_list: D014408:Biomarkers, Tumor; D019275:Radiopharmaceuticals; D015021:Yttrium Radioisotopes